Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 2/20 | 0.66 |
| ▸ | CPB1 | P15086 | 1/20 | 0.66 |
| ▸ | CPA3 | P15088 | 1/20 | 0.66 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.50 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL901408 | 1.00 | CPA1 (0.66) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL1914987 | 1.00 | CPA1 (0.66) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL1912582 | 0.91 | MMEL1 (0.60) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL7506768 | 0.88 | KMT2A (0.54) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL9755831 | 0.88 | KMT2A (0.54) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL10441763 | 0.87 | LTA4H (0.64) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL8999162 | 0.87 | KMT2A (0.53) | CPA1CPB1CPA3CPB2KMT2A | |
| SCHEMBL3965849 | 0.87 | ESR1 (0.58) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL7752235 | 0.87 | KMT2A (0.53) | CPA1CPB1CPA3CPB2LTA4H | |
| SCHEMBL22943094 | 0.87 | ANPEP (0.56) | CPA1CPB1CPA3CPB2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| US-8222215-B2 | Methods for the use of inhibitors of antigen presentation by MHC class II molecules | PROVID PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8222215-B2 | Methods for the use of inhibitors of antigen presentation by MHC class II molecules | PROVID PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | disclosed |
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | PROVID PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | PROVID PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2009073168-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | PROVID PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | PROVID PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | PROVID PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-7439231-B2 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | PROVID PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439231-B2 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | PROVID PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
| EP-0561758-A2 | Method of preparing optically active homo-beta-amino acids | MONSANTO COMPANY (US) | 1993-09-22 | — | — | EP | disclosed |
| US-5229369-A | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| WO-1990000050-A1 | AMINOALKYLAMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0349922-A2 | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | HLA-DRB1, CD74, MICA | CPA1 792/4885CPB1 431/4885CPA3 632/4885 |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | CPA1 953/4885CPB1 939/4885CPA3 739/4885 |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | CPA1 556/4885CPB1 515/4885CPA3 344/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | CPA1 805/4885CPB1 2097/4885CPA3 1493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.